Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Johann Sebastian De Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019
Cited by 236 works. doi:10.1016/s1470-2045(18)30859-3
Authors
- Johann Sebastian De Bono
- Nicole Concin
- David S. Hong
- Fiona C. Thistlethwaite
- Jean-Pascal Machiels
- Hendrik‐Tobias Arkenau
- Ruth Plummer
- Dorte Lisbet Nielsen
- Kristian Windfeld
- Srinivas Ghatta
- Brian M. Slomovitz
- James F. Spicer
- Jeffrey Yachnin
- Joo Ern Ang
- Morten Mau‐Sørensen
- Martin David Forster
- Dearbhaile Catherine Collins
- Emma Jane Dean
- Reshma A. Rangwala
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- Role of Tissue Factor in Cancer
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- The relationship between tissue factor and cancer progression: insights from bench and bedside
- Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma
- New developments for antibody-drug conjugate-based therapeutic approaches
- Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis
- An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors